Literature DB >> 33321078

The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing.

Thiruvinvamalai S Dharmarajan1.   

Abstract

Proton pump inhibitors (PPIs) are proven medications of choice for gastroesophageal reflux disease (GERD), acid-related disorders, erosive esophagitis, Barrett esophagus, prevention of gastrointestinal bleeding while on nonsteroidal anti-inflammatory drugs, eosinophilic esophagitis, peptic ulcer disease, stress ulcer prophylaxis in critically ill patients, and other indications. Best practice guidelines from several sources on the appropriate indications and duration of PPI therapy have been summarized for easy assimilation. Individualized decision with regard to PPI use is illustrated by case vignettes; best approaches are provided. The significant increase in use of PPIs for ill-defined indications over the years, associated adverse outcomes with long-term use, and consequent increase in health care costs have drawn much attention. Adverse outcomes due to PPI therapy may be categorized as unrelated or related to gastric acid inhibition. Examples of outcomes unrelated to acid inhibition include allergic reactions, acute interstitial nephritis, chronic kidney disease, poor cardiovascular outcomes, dementia, and drug interactions; consequences of acid inhibition include gastrointestinal infections, pneumonia, nutrient deficiencies, fractures, spontaneous bacterial peritonitis, and small intestinal bacterial overgrowth. Provider awareness regarding best practice guidelines on PPI use and imparting pertinent education to patients may be the rational approach to safe and effective PPI therapy. In individuals in whom the drug is not indicated, efforts at deprescribing the PPI may be attempted following discussion with the patient. Approaches include stopping the drug, reducing the dose or using "on-demand" therapy after completing the course of treatment for the specific indication. Barriers to successful deprescribing exist. Follow-up is recommended for recurrence of manifestations; in the event of recurrence, the PPI may need to be re-instituted. PPIs are valuable, irreplaceable drugs in the prevention and treatment of certain disorders for specific durations of time. Evidence nevertheless suggests that excessive and inappropriately prolonged use of PPIs is associated with a broad range of adverse effects. Education of provider and patient, stewardship, and motivation are key to appropriate use of PPIs for the right indications. Key implications for practice are offered.
Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PPIs and dementia; PPIs and duration of therapy; PPIs and infections; PPIs and mortality; PPIs and outcomes; Proton pump inhibitors; best practice guidelines for use of PPIs; deprescribing of PPIs; indications for PPIs; long-term vs short-term use of PPIs; use and misuse of PPIs; value of prescribing PPIs

Year:  2020        PMID: 33321078     DOI: 10.1016/j.jamda.2020.09.046

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  5 in total

1.  People exposed to proton-pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: A nationwide matched cohort study.

Authors:  Ivan Kodvanj; Jan Homolak; Vladimir Trkulja
Journal:  Br J Clin Pharmacol       Date:  2022-09-12       Impact factor: 3.716

Review 2.  [Pneumonia in old age].

Authors:  Helmut Frohnhofen; Sven Stieglitz
Journal:  Pneumologe (Berl)       Date:  2021-03-16

3.  Patients, Prescribers, and Institutional Factors Associated with Inappropriate Use of Acid Suppressive Therapy in Medical Wards: An Experience of a Single-Center in Saudi Arabia.

Authors:  Ghazwa B Korayem; Raghad Alkanhal; Raghad Almass; Sarah Alkhunaizan; Ghada Alharthi; Nader Bin Sheraim; Sara Alqahtani; Hadeel Alkofide
Journal:  Int J Gen Med       Date:  2021-08-30

4.  The Association Between Proton Pump Inhibitors and COVID-19 is Confounded by Hyperglycemia in a Population-Based Study.

Authors:  Asher Shafrir; Ariel A Benson; Lior H Katz; Tiberiu Hershcovici; Menachem Bitan; Ora Paltiel; Ronit Calderon-Margalit; Rifaat Safadi; Michal Shauly-Aharonov
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

5.  The Janus-like Association between Proton Pump Inhibitors and Dementia.

Authors:  Anna Papazoglou; Muhammad I Arshaad; Christina Henseler; Johanna Daubner; Karl Broich; Britta Haenisch; Marco Weiergräber
Journal:  Curr Alzheimer Res       Date:  2021       Impact factor: 3.498

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.